基线PET影像组学在弥漫性大B细胞淋巴瘤结局预测中优于IPI风险评分
本研究外部验证HOVON-84试验开发的临床PET模型,并比较其与IPI的预测性能。共纳入1195例弥漫性大B细胞淋巴瘤患者,其中887例来自6项研究作为外部验证集。临床PET模型AUC为0.71,显著高于IPI的0.62(P < .001),且在全部6项研究中预测性能均优于IPI。
要点
- 临床PET模型(MTV、Dmaxbulk、SUVpeak、体能状态、年龄)预测2年PFS的AUC为0.71,IPI为0.62(P < .001)。
- 高危IPI患者2年PFS为61.4%,高危临床PET患者为51.9%,PPV从35.5%升至49.1%。
- 66.4%高危IPI患者无进展或复发,高危临床PET患者为55.5%,PPV从33.7%升至44.6%。
核心结论
- 临床PET模型在6项独立一线DLBCL研究中均保持对结局的预测能力,且在所有研究中模型性能均高于目前使用的IPI。
研究设计与样本
- 研究纳入1195例弥漫性大B细胞淋巴瘤患者,其中887例来自6项研究的数据作为外部验证集,用于验证HOVON-84试验开发的临床PET模型并与IPI比较。
主要发现
- IPI的AUC为0.62,临床PET模型的AUC为0.71,差异显著(P < .001)。
- 高危IPI患者2年PFS为61.4%,高危临床PET患者为51.9%,PPV从35.5%升至49.1%。
- 66.4%的高危IPI患者无进展或复发,高危临床PET评分为55.5%,PPV从33.7%升至44.6%。
- 临床PET模型在6项独立一线DLBCL研究中均保持对结局的预测能力,且在所有研究中模型性能均高于目前使用的IPI。
关键数值与推荐
- 临床PET模型提取的指标包括代谢肿瘤体积(MTV)、最大病灶与另一病灶间最大距离(Dmaxbulk)和峰值标准化摄取值(SUVpeak),并结合体能状态和年龄。
- 主要结局为2年无进展生存(PFS)和2年进展时间(TTP)。
- 模型性能用曲线下面积(AUC)评估,诊断性能用阳性预测值(PPV)评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study is to externally validate the clinical positron emission tomography (PET) model developed in the HOVON-84 trial and to compare the model performance of our clinical PET model using the international prognostic index (IPI). In total, 1195 patients with diffuse large B-cell lymphoma (DLBCL) were included in the study. Data of 887 patients from 6 studies were used as external validation data sets. The primary outcomes were 2-year progression-free survival (PFS) and 2-year time to progression (TTP). The metabolic tumor volume (MTV), maximum distance between the largest lesion and another lesion (Dmaxbulk), and peak standardized uptake value (SUVpeak) were extracted. The predictive values of the IPI and clinical PET model (MTV, Dmaxbulk, SUVpeak, performance status, and age) were tested. Model performance was assessed using the area under the curve (AUC), and diagnostic performance, using the positive predictive value (PPV). The IPI yielded an AUC of 0.62. The clinical PET model yielded a significantly higher AUC of 0.71 (P < .001). Patients with high-risk IPI had a 2-year PFS of 61.4% vs 51.9% for those with high-risk clinical PET, with an increase in PPV from 35.5% to 49.1%, respectively. A total of 66.4% of patients with high-risk IPI were free from progression or relapse vs 55.5% of patients with high-risk clinical PET scores, with an increased PPV from 33.7% to 44.6%, respectively. The clinical PET model remained predictive of outcome in 6 independent first-line DLBCL studies, and had higher model performance than the currently used IPI in all studies.
引用
- Eertink JJ, Zwezerijnen GJC, Heymans MW, et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023. PMID: 37001036. doi:10.1182/blood.2022018558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。